NanoViricides drug asset shows ‘superior antiviral effects’ against Influenza A
NanoViricides (NYSE-A:NNVC) announced that its lead drug asset NV-387 has shown ultra-broad antiviral activity, including against Influenza A viruses. The...…
1,260€
1,61%
Echtzeit-Aktienkurs Nanoviricides Inc.
Bid:
Ask:
Nachrichten zur Nanoviricides Inc. Aktie
NanoViricides completes Phase 1 trial of lead asset NV-387
NanoViricides (NYSE-A:NNVC) announced that a Phase 1 trial of its investigational therapeutic NV-387 has been completed. The company, a leader…
NanoViricides completes Phase 1 trial for respiratory viral infection candidate
NanoViricides (NYSE-A:NNVC) announced that a Phase 1 trial of its investigational therapeutic NV-387 has been completed. The company, a leader…